Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: Case report and review of the nomenclature of vital blue dyes

Annals of Allergy, Asthma and Immunology

Volumn 96, Issue 3, 2006, Pages 497-500

  Scherer, Kathrin ^a   Studer, Wolfgang ^b   Figueiredo, Verena ^a   Bircher, Andreas J ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD63 ANTIGEN; DISULFINE BLUE; DYE; IMMUNOGLOBULIN E; ISOSULFAN BLUE;

AGED; ALLERGENICITY; ANAPHYLAXIS; ANTIGEN EXPRESSION; CASE REPORT; CROSS REACTION; FEMALE; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; INTRAOPERATIVE PERIOD; LYMPHATIC SYSTEM; NOMENCLATURE; PRIORITY JOURNAL; REVIEW; SENSITIZATION; SENTINEL LYMPH NODE BIOPSY; SKIN TEST;

EID: 33645237425     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60921-0     Document Type: Article

References (24)

1. Currie M, Webb RK, Williamson JA, et al. The Australian Incidence Monitoring Study: clinical anaphylaxis: an analysis of 2000 incidence report. Anaesth Intensive Care. 1993;21:621-625.
2. Mertes PM, Laxenaire MC. Allergy and anaphylaxis in anesthesia. Minerva Anestesiol. 2004;70:285-291.
3. Mertes PM, Alla F, Laxenaire MC. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology. 2003;99:536-545.
4. Lieberman P, Kemp SF, Oppenheimer J, et al. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005;115:S483-S523.
5. Ikeda T, Jinno H, Fujii H, Kitajima M. Recent development of sentinel lymph node biopsy for breast cancer in Japan. Asian J Surg. 2004;27:275-278.
6. Correction for Tsopelas and Sutton [erratum]. J Nucl Med. 2003;44:649.
7. Quiliquini A, Hogendijk S, Hauser C. Anaphylaxis to patent blue [letter]. Dermatology. 1998;197:400.
8. Ebo DG, Wets RD, Spiessens TK, Bridts CH, Stevens WJ. Flow-assisted diagnosis of anaphylaxis to patent blue. Allergy. 2005;60:703-704.
9. Leong SPL, Donegan E, Heffernon W, et al. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000;7:361-366.
10. Montgomery LL, Thorne AC, Van Zee KJ, et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg. 2002;95:385-388.
11. Sprung J, Tully MJ, Ziser A. Anaphylactic reactions to isosulfan blue dye during sentinel node lymphadenectomy for breast cancer. Anesth Analg. 2003;96:1051-1053.
12. Efron P, Knudsen E, Hirshorn S, Copeland EM III. Anaphylactic reaction to isosulfan blue used for sentinel node biopsy: case report and literature review. Breast J. 2002;8:396-399.
13. Brown SGA. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114:371-376.
14. Ober AI, MacLean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol. 2003; 112:1008-1009.
15. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med. 1992;327:380-384.
16. Lee JM, Greenes DS. Biphasic anaphylactic reactions in pediatrics. Pediatrics. 2000;106:762-766.
17. Albo D, Wayne JD, Hunt KK, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001;182:393-398.
18. Raut CP, Daley MD, Hunt KK, et al. Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol. 2004;22: 567-568.
19. Coleman RL, Whitten CW, O'Boyle J, Sidhu B. Unexplained decrease in measured oxygen saturation by pulse oximetry following injection of lymphazurin 1% (isosulfan blue) during a lymphatic mapping procedure. J Surg Oncol. 1999;70:126-129.
20. Laurie SA, Khan DA, Gruchalla RS, Peters G. Anaphylaxis to isosulfan blue. Ann Allergy Asthma Immunol. 2002;88:64-66.
21. Woehrl S, Focke M, Hinterhuber G, et al. Near fatal anaphylaxis to patent blue V. Br J Dermatol. 2004;150:1037-1038.
22. Longnecker SM, Guzzardo MM, Van Voris LP. Life threatening anaphylaxis following subcutaneous administration of isosulfan blue 1%. Clin Pharmacol. 1985;4:219-221.
23. Nour A. Efficacy of methylene blue dye in localization of sentinel lymph node in breast cancer patients. Breast J. 2004;10:388-391.
24. Tsopelas C, Sutton R. Why certain dyes are useful for localizing the sentinel lymph node. J Nucl Med. 2002;43:1377-1382.